PCVX Reiterated by Cantor Fitzgerald -- Price Target Announced a
Cantor Fitzgerald reiterated its Overweight rating for Vaxcyte (PCVX) with a $120.00 price target. The company has a $10.62B market cap, negative earnings, and a GF Score of 36/100. Insiders sold $6.32M in shares over three months. Analysts see growth potential in its vaccine candidates, but profitability and growth remain challenges.
How this was made
The 30-second read
Why it matters
The new Overweight rating and $120 target provide a fresh catalyst that could move the stock.
Market read
Analyst upgrade may generate buying pressure in the short term, but fundamentals remain weak.
What to watch
Negative earnings and profitability challenges could limit upside.
Background
Vaxcyte is a clinical‑stage vaccine developer with a $10.6B market cap and negative earnings.
Ticker impact
Cantor Fitzgerald reiterated an Overweight rating and set a new $120 price target for Vaxcyte, up from its current $71.38 price.
potential upward pressure as investors price in the $120 target
The rating change and target are fresh analyst guidance, providing a clear catalyst for short‑term buying.
Market effects
May lift sentiment toward biotech stocks with vaccine pipelines.
Limited to US biotech sector.
Low
Counterpoint
Insider selling and modest GF score suggest caution despite the upgrade.
Key entities
- CompanyVaxcyte Inc.
Biotech firm developing conjugate and protein vaccines.
- AnalystCantor Fitzgerald
Equity research firm issuing the rating update.
